Attenuation of relapsing fever neuroborreliosis in mice by IL-17A blockade.

Abstract

Relapsing fever due to <i>Borrelia hermsii</i> is characterized by recurrent bacteremia episodes. However, infection of <i>B. hermsii</i>, if not treated early, can spread to various organs including the central nervous system (CNS). CNS disease manifestations are commonly referred to as relapsing fever neuroborreliosis (RFNB). In the mouse model of <i>B. hermsii</i> infection, we have previously shown that the development of RFNB requires innate immune cells as well as T cells. Here, we found that prior to the onset of RFNB, an increase in the systemic proinflammatory cytokine response followed by sustained levels of IP-10 concurrent with the CNS disease phase. RNA sequencing analysis of the spinal cord tissue during the disease phase revealed an association of the interleukin (IL)-17 signaling pathway in RFNB. To test a possible role for IL-17 in RFNB, we compared <i>B. hermsii</i> infection in wild-type and IL-17A^-/- mice. Although the onset of bacteremia and protective anti-<i>B. hermsii</i> antibody responses occurred similarly, the blood-brain barrier permeability, proinflammatory cytokine levels, immune cell infiltration in the spinal cord, and RFNB manifestations were significantly diminished in IL-17A^-/- mice compared to wild-type mice. Treatment of <i>B. hermsii</i>-infected wild-type mice with anti-IL-17A antibody ameliorated the severity of spinal cord inflammation, microglial cell activation, and RFNB. These data suggest that the IL-17 signaling pathway plays a major role in the pathogenesis of RFNB, and IL-17A blockade may be a therapeutic modality for controlling neuroborreliosis.